Seahawks fantasy insider Scott Engel looks ahead to 2026 and spotlights Jaxon Smith-Njigba’s historic fantasy season.

Smith-Njigba’s 2025 season was even better than his 2024 campaign—and that’s putting it lightly. At one point in the year, ...

Former USC quarterback Sam Darnold’s redemption story has been exciting for NFL fans to watch over the past two seasons. After last season’s tremendous run with ...

Fears that the injury to the Welsh club's talisman could derail their play-off bid have been eased by his impressive ...

Jaxon Smith-Njigba got a major boost from the San Francisco 49ers' plan to cover the Seattle Seahawks star wide receiver in ...

Seahawks' Sam Darnold joins Tom Brady, Peyton Manning, in 13-win NFL history originally appeared on The Sporting News. Add ...

Investing.com - Vir Biotechnology (NASDAQ:VIR) shares are likely to trade higher after the company announced a commercialization partnership with European specialty pharmaceutical company Norgine for ...

Vir Biotechnology is handing off certain commercial rights for its hepatitis D program to European specialty pharma Norgine in a licensing deal that’s worth up to 550 million euros ($645 million) and ...

Agreement underscores Norgine's mission to bring innovative therapies to patients and builds on our heritage in hepatology and specialty pharmaceuticals. Vir Biotechnology's chronic hepatitis delta ...